EX-99.1 2 ea022758401ex99-1_regencell.htm FORM OF LETTER OF LOCK-UP UNDERTAKING

Exhibit 99.1

 

FORM OF FORTH EXTENSION OF LETTER OF LOCK-UP UNDERTAKING

 

Date:

 

From:                                         (the “Optionee”)

 

To:Regencell Bioscience Holdings Limited (the “Company”)

 

References are made in this forth extension of the letter of lock-up undertaking (this “Fourth Extension of Lock-Up Undertaking”) to:

 

1.An agreement of option to purchase ordinary shares of Regencell Bioscience Holdings Limited dated June 9, 2021, under which the Company granted certain options (the “Options”) to purchase ordinary shares of the Company in the amounts set forth therein;

 

2.A letter of lock-up undertaking by the Optionee dated May 6, 2022, under which the Optionee undertook to the Company, within the period of one year and six months immediately following the closing of the initial public offering of the Company, not to, and to procure any entities controlled by the Optionee and any trusts of which the Optionee is a beneficiary not to, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise transfer or dispose of any of the Options or shares issued upon exercise of the Options (the “Lock-Up Undertaking”);

 

3.A letter of lock-up undertaking by the Optionee dated October 12, 2022, under which the Optionee undertook to the Company to extend the Lock-Up Undertaking for an additional six months (the “First Extension of the Lock-Up Undertaking”);

 

4.A letter of lock-up undertaking by the Optionee dated April 19, 2023, under which the Optionee undertook to the Company to extend the Lock-Up Undertaking and the First Extension of the Lock-Up Undertaking for an additional six months (the “Second Extension of the Lock-Up Undertaking”);

 

5.A letter of lock-up undertaking by the Optionee dated November 24, 2023, under which the Optionee undertook to the Company to extend the Lock-Up Undertaking for an additional twelve months (the “Third Extension of the Lock-Up Undertaking”), (collectively, the “Lock-Up Undertakings”).

 

For good and valuable consideration received by the Optionee from the Company, the Optionee hereby agrees to enter into this Fourth Extension of Lock-Up Undertaking to extend the Lock- Up Undertakings for an additional fifteen months until April 20, 2026.

 

The laws of New York shall govern the interpretation, validity, administration, enforcement, and performance of the terms of this Fourth Extension of Lock-Up Undertaking, regardless of the law that might be applied under principles of conflicts of laws.

 

[The remainder of this page is intentionally left blank]

 

 

 

 

IN WITNESS WHEREOF, the Optionee has executed this letter agreement as of the date first set forth above.

 

   
   
Acknowledged by  
Regencell Bioscience Holdings Limited  
   
   
Yat-Gai Au  
Chief Executive Officer  

 

Signature Page of Forth Extension of Letter of Lock-Up Undertaking